Swissmedic urges medical device manufacturers to review their post-market surveillance (PMS) documentation after finding major non-conformities in recent assessments. Learn more about compliance with MedDO requirements
MD
Mutual recognition of regulations between the EU and Switzerland
Discover how the EU and Switzerland maintain strong trade relations through mutual regulation agreements, enabling smoother market access for many products.
Swiss Medtech sector study: increasing hurdles for market authorisation seen as biggest challenge
In September 2024, Swiss MedTech released its new sector study for 2024, highlighting the significant…
Swissdamed actors module goes live
In the last week of June 2024, Swissmedic announced the go-live date for the actors…
Classification of products containing essential oils in Switzerland
In June 2024, Swissmedic published together with other competent authorities a guidance document on the…
How to sell legacy medical devices on the Swiss market after 26 May 2024
In May 2024, Swiss Medtech published a guidance document on how to sell medical devices…
How are medical devices and cosmetics with CBD regulated in Switzerland?
In April 2024, Swissmedic updated a guidance document on products containing cannabidiol (CBD) and other…
Negotiations open between Switzerland and the EU
On 18 March 2024, Swiss President Viola Amherd and European Commission President Ursula von der…
A closer look at Swissdamed and its implementation timeline: actor registration in 2024
In February 2024, the Swiss Agency for Therapeutic Products (Swissmedic) announced that the actor registration…
Swiss regulatory updates that marked the beginning of the year
Swissmedic, the Swiss Agency for Therapeutic Products, is responsible for carrying out the control tasks…